David is the CEO of AGTC and Chair of the Oxular Board. He has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously CEO of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the company through a successful NASDAQ listing and M&A transaction. He was previously Vice President of Johnson & Johnson’s Vision Care Franchise, and, prior to that, held several roles at Allergan for 25 years, including Regional President. He is also a Board member of Jaguar Gene Therapy, Axovia Therapeutics, and the Glaucoma Foundation.